[CAS NO. 72558-82-8] Ceftazidime

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [72558-82-8]

Catalog

HY-B0593

Brand

MCE

CAS

72558-82-8

DESCRIPTION [72558-82-8]

Overview

MDL	MFCD00072034
Molecular Weight	546.58
Molecular Formula	C22H22N6O7S2
SMILES	O=C1[C@@H](NC(/C(C2=CSC(N)=N2)=N\OC(C)(C(O)=O)C)=O)[C@@]3([H])SCC(C[N+]4=CC=CC=C4)=C(C([O-])=O)N13

For research use only. We do not sell to patients.

12 Publications Citing Use of MCE

Summary

Ceftazidime (GR20263), an antibiotic , has a broad spectrum activity against Gram-positive and Gram-negative aerobic bacteria. Ceftazidime is also active against Enterobacteriaceae (including β-lactamase-positive strains) and is resistant to hydrolysis by most β-lactamases ^[1] .

In Vitro

Ceftazidime (0-8 µg/mL approximately, 24 h) displays antibacterial and anti-biofilm activities against P. aeruginosa strains ^[2] .
Ceftazidime (0-40 µg/mL approximately, 18-20 h) has inhibitory activities against S. maltophilia isolates ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	P. aeruginosa strains (PAO1, PA1, PA2)
Concentration:	0-8 µg/mL approximately
Incubation Time:	24 h
Result:	Displayed antibacterial and anti-biofilm activities with MIC values of 2-4 µg/mL.

In Vivo

Ceftazidime (2 h infusion of injection, 2 000 mg, every 8 h for 24 h) moderately reduces bacterial density in a murine thigh infection model ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine thigh infection model ^[4]
Dosage:	2000 mg
Administration:	2 h infusion of injection, every 8 h for 24 h.
Result:	Reduced bacterial density against the isogenic NDM (New Delhi metallo-β-lactamase) strain.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01785641	Chulalongkorn University	Peritonitis	December 2012	Not Applicable
NCT00210899	Basilea Pharmaceutica	Skin Diseases, Infectious\|Skin Diseases, Bacterial\|Staphylococcal Skin Infections	September 2005	Phase 3
NCT01455246	University of Padova	Cirrhosis\|Ascites\|Nosocomial Spontaneous Bacterial Peritonitis	October 2010	Phase 2\|Phase 3
NCT04961580	Children´s Hospital of Fudan University	Sepsis\|Antibiotic Reaction	December 1, 2022
NCT01784445	University Hospital Rijeka	Pancreatitis	June 2013	Phase 4
NCT00210964	Basilea Pharmaceutica	Pneumonia	April 2005	Phase 3
NCT00195923	Children´s Mercy Hospital Kansas City	Perforated Appendicitis	April 2005
NCT00921024	Cubist Pharmaceuticals LLC	Complicated Urinary Tract Infection	June 30, 2009	Phase 2
NCT05105035	Arrevus Inc.\|Aceragen	Melioidosis	June 14, 2022	Phase 2
NCT01044719	Imperial College London	Cystic Fibrosis	January 2010	Phase 4
NCT04948463	Murdoch Childrens Research Institute	Febrile Neutropenia	November 15, 2021	Phase 4
NCT02840136	University Ghent\|King Baudouin Foundation\|Belgische Vereniging voor Strijd tegen Mucoviscidose	Cystic Fibrosis	February 2016	Not Applicable
NCT00229008	Basilea Pharmaceutica	Pneumonia	November 2005	Phase 3
NCT04187755	Indonesia University	Neutropenia, Febrile\|Leukemia\|Pediatric Cancer\|Antibiotic Reaction	March 1, 2019	Phase 4
NCT02837835	CHU de Reims	Pneumonia	March 2005	Phase 3
NCT01667094	The Alfred	Cystic Fibrosis	September 2012	Phase 4
NCT01344512	University Hospital, Bordeaux	Pediatrics\|Ceftazidime\|Ciprofloxacin\|Voriconazole	June 2011	Not Applicable
NCT00153634	Seattle Children´s Hospital\|Cystic Fibrosis Foundation	Cystic Fibrosis\|Chronic Bronchitis	March 2004	Not Applicable
NCT01644643	Pfizer\|Forest Laboratories	Complicated Urinary Tract Infection\|Complicated Intra-abdominal Infection	January 2013	Phase 3
NCT00786305	Groupe Hospitalier Pitie-Salpetriere	Pneumonia	October 2004	Phase 2
NCT02872038	Chulalongkorn University\|The Kidney Foundation of Thailand\|Siam Pharmaceutical Co Ltd	Peritoneal Dialysis Associated Peritonitis	August 2015	Phase 4
NCT00173901	National Taiwan University Hospital	Infection	March 2001	Phase 4
NCT03404739	Shanghai Zhongshan Hospital	Esophageal Achalasia	October 1, 2017	Phase 2\|Phase 3
NCT02475733	Pfizer	Complicated Intra-abdominal Infections	August 1, 2015	Phase 2
NCT00823238	University of North Carolina, Chapel Hill\|Cystic Fibrosis Foundation	Cystic Fibrosis	July 2004	Phase 1
NCT05487586	Pfizer	Hospital Acquired Pneumonia\|Ventilator Acquired Pneumonia\|Complicated Intra Abdominal Infections	October 18, 2022
NCT01290900	Pfizer	Healthy Male Volunteers	February 2011	Phase 1
NCT01599806	Pfizer\|Forest Laboratories	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	October 2012	Phase 3
NCT04402359	King Abdul Aziz Specialist Hospital	Ventilator Associated Pneumonia	July 5, 2018
NCT01430910	Pfizer	Healthy	September 2011	Phase 1
NCT03754387	Zunyi Medical College	Chronic Appendicitis	January 1, 2019	Not Applicable
NCT04771884	Shandong University\|Children´s Hospital of Chongqing Medical University	Bacterial Meningitis\|Augmented Renal Clearance	October 1, 2020
NCT03376529	Spero Therapeutics\|Simbec Research\|QPS	Healthy Volunteers	November 10, 2017	Phase 1
NCT04319328	University of Manitoba\|The Kidney Foundation of Canada	Hemodialysis Complication\|Infectious Disease\|End Stage Renal Disease	October 18, 2019
NCT00579956	University of Oxford\|Mahidol University\|Wellcome Trust	Melioidosis	December 2007	Not Applicable
NCT00333385	Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche\|Vaincre la Mucoviscidose\|GlaxoSmithKline\|Baxter Healthcare Corporation\|Roche Pharma AG	Cystic Fibrosis\|Pseudomonas Aeruginosa\|Pulmonary Exacerbation	October 2001	Phase 4
NCT01595438	Pfizer\|Forest Laboratories	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	October 2012	Phase 3
NCT02497781	Pfizer\|PRA Health Sciences	Complicated Urinary Tract Infections	September 24, 2015	Phase 2
NCT02526004	University College Cork\|Queen´s University, Belfast\|University of Paris 5 - Rene Descartes\|University of Dundee\|University of Washington\|University Hospital Heidelberg\|Teagasc\|Clininfo S.A.\|GABO:mi\|Papworth Hospital NHS Foundation Trust\|KU Leuven\|Assistance Publique - Hôpitaux de Paris\|European Union	Cystic Fibrosis	October 1, 2013	Not Applicable
NCT02787057	Peking University First Hospital	Peritoneal Dialysis Associated Peritonitis	November 2012	Not Applicable
NCT00752882	University Hospital, Clermont-Ferrand	Pseudomonas Aeruginosa Meningitis		Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 182.96 mM ; Need ultrasonic)

DMSO : 25 mg/mL ( 45.74 mM ; ultrasonic and warming and heat to 80°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8296 mL	9.1478 mL	18.2956 mL
5 mM	0.3659 mL	1.8296 mL	3.6591 mL
10 mM	0.1830 mL	0.9148 mL	1.8296 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (182.96 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Pyridinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt

Pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]-

Pyridinium, 1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt

GR 20263

Ceftazidime

Fortaz

Modacin

Fortum

Biotum

(6R,7R)-7-[(Z)-2-(Aminothiazol-4-yl)-2-(2-carboxypropoxyimino)acetamido]-3-(1-pyridiniummethyl)ceph-3-em-4-carboxylate

Tazidime

Tazicef

Ceftazidine

Ceftacidin

Fortam

Tazid

Tizime

Cefazid

Zidim

Solvetan